Article Versions Notes

Rathbone M, O’Hagan C, Wong H, Khan A, Cook T, Rose S, Heseltine J, Escriu C. Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations. Cancers. 2024; 16(7):1249. https://doi.org/10.3390/cancers16071249

Rathbone, Marcus, Conor O’Hagan, Helen Wong, Adeel Khan, Timothy Cook, Sarah Rose, Jonathan Heseltine, and Carles Escriu. 2024. "Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations" Cancers 16, no. 7: 1249. https://doi.org/10.3390/cancers16071249

Rathbone, M., O’Hagan, C., Wong, H., Khan, A., Cook, T., Rose, S., Heseltine, J., & Escriu, C. (2024). Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations. Cancers, 16(7), 1249. https://doi.org/10.3390/cancers16071249